Actuate Therapeutics Inc. (ACTU)
NASDAQ: ACTUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACTU stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.60M
- EPS (TTM)
- -$0.76
- Dividend yield
- None
- 52-week range
- 0.174 – 7.90
- Day range
- 0.20 – 0.2475
- Volume / Avg
- 629.80K / 807.24K
- Beta
- —
- Shares outstanding
- 60.38M
52-week range
ACTU stock today
Actuate Therapeutics (ACTU) closed at $0.2253 on Nov 20, up 5.38% (+$0.0115), versus the S&P 500's 3.70% decline. Shares are 97.1% below their 52-week high of $7.90, set on Dec 10, 2025 and 29.5% above the 52-week low of $0.174, near the bottom of the past year's range. ACTU is down 96.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 96.4%.
Actuate Therapeutics has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Actuate Therapeutics
Company profileActuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel M. Schmitt
- Headquarters
- Fort Worth, TX
- Employees
- 12
- IPO year
- 2024
- Website
- actuatetherapeutics.com
Financial highlights
Full financialsActuate Therapeutics reported a net loss of $22.2 million, compared with a loss of $27.3 million a year earlier. Diluted earnings per share came in at -$1.06.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-22.23M | $-27.29M | $-24.74M |
| EPS (diluted) | $-1.06 | $-3.26 | $-17.24 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$11.68+5084.20%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.14 vs $-0.18
- Surprise
- +22.22%
ACTU news
All ACTU news- Actuate Reports Up To 77% Tumor Growth Inhibition With Oral Elraglusib In Melanoma ModelNasdaqACTU, BRK.A
- Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026GlobeNewswire
- Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma DataNasdaqACTU, LEN.B
- Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026GlobeNewswire
- Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral TabletsGlobeNewswire
- Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public OfferingGlobeNewswire
- TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in SchizophreniaNasdaqTEVA, SNY, CRSP, ACTU
- AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerNasdaqABBV, BMY, CRSP, ACTU
Actuate Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs ACTU |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs ACTU |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs ACTU |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs ACTU |
| NEUPNeuphoria Therapeutics Inc. | 2.35 | +1.29% | $12.72M | vs ACTU |
| MCRBSeres Therapeutics Inc. | 1.24 | -6.77% | $12.64M | vs ACTU |
| ALLRAllarity Therapeutics Inc. | 0.785 | -9.25% | $12.56M | vs ACTU |
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs ACTU |
Indexes, lists and sector
Actuate Therapeutics stock FAQ
What is Actuate Therapeutics's stock price today?
ACTU last traded at $0.2253 as of Nov 20, 4:00 PM EST, up 5.38% on the day. Prices are delayed at least 15 minutes.
Who is Actuate Therapeutics's CEO?
Mr. Daniel M. Schmitt is the chief executive officer of Actuate Therapeutics Inc., which has about 12 employees.
What is the ACTU 52-week high?
The 52-week high for ACTU is $7.90 and the 52-week low is $0.174. The stock is currently 97.1% below its high.